Paper Details
- Home
- Paper Details
Pharmacokinetic properties of the antimalarial combination therapy artemether-lumefantrine in normal-weight, overweight and obese healthy male adults.
Author: DavisTimothy M E, DavisWendy A, DrinkwaterJocelyn J, Page-SharpMadhu, SalmanSam, SugiartoSri Riyati
Original Abstract of the Article :
The component drugs in the widely used antimalarial artemisinin combination therapy artemether-lumefantrine are lipophilic, with the possibility that recommended fixed doses in adults may lead to subtherapeutic concentrations and consequent treatment failure in overweight/obese individuals with mala...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元:
https://doi.org/10.1016/j.ijantimicag.2021.106482
データ提供:米国国立医学図書館(NLM)
Pharmacokinetic Properties of Artemether-Lumefantrine in Overweight and Obese Individuals
This research explores a critical question in the field of infectious diseases: how does body weight impact the effectiveness of antimalarial medications? The study delves into the pharmacokinetic properties of artemether-lumefantrine, a widely used antimalarial combination therapy, in healthy male volunteers with varying body mass indexes (BMI). The researchers employed a rigorous methodology, using liquid chromatography-mass spectrometry to measure plasma drug/metabolite concentrations and incorporate them into multi-compartmental population pharmacokinetic models. Their findings provide valuable insights into the relationship between body weight and drug efficacy.
No Need for Dose Modification in Overweight and Obese Patients
The study revealed a non-significant trend toward a lower area under the plasma concentration-time curve (AUC) with higher body weight or BMI for dihydroartemisinin and, particularly, artemether. However, this trend was attenuated when the dose was normalized for mg/kg. Interestingly, this relationship was not observed for the more lipophilic lumefantrine and its metabolite desbutyl-lumefantrine. The simulated Day 7 plasma lumefantrine concentrations remained above 200 µg/L, which is the threshold required to minimize Plasmodium falciparum recrudescences, in all participants.
Implications for Malaria Treatment
The results suggest that dose adjustments are not necessary for artemether-lumefantrine in overweight and obese patients with malaria. This is reassuring news for healthcare providers, as it simplifies treatment regimens and ensures consistent therapeutic efficacy. The findings highlight the importance of accounting for individual patient characteristics, including BMI, when evaluating drug pharmacokinetics. This knowledge is crucial for optimizing treatment strategies and improving patient outcomes.
Dr.Camel's Conclusion
It's great to know that overweight and obese patients with malaria don't need special dose adjustments for artemether-lumefantrine. It's like saying that a camel can navigate a sandy desert without needing a map; the medication will effectively target the parasites without any extra effort. This research provides valuable guidance for healthcare professionals, ensuring that everyone has equal access to effective malaria treatment.
Date :
- Date Completed 2022-03-07
- Date Revised 2022-03-07
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.